Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a Safety, Acceptability and Pharmacokinetics Study of Q-Griffithsin Intranasal Spray for Broad-spectrum Coronavirus Pre-exposure Prophylaxis: A Study of the PREVENT-COVID-19Program

NCT05122260 is registered in ClinicalTrials.gov with Kenneth Palmer as lead sponsor.

NCT NCT05122260
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05122260 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a Safety, Acceptability and Pharmacokinetics Study of Q-Griffithsin Intranasal Spray for Broad-spectrum Coronavirus Pre-exposure Prophylaxis: A Study of the PREVENT-COVID-19Program
Lead sponsor
Kenneth Palmer
Phase
Phase 1
Overall status
Completed
Start date
November 11, 2021
Completion date
February 14, 2022
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 prevention